Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Tumor-Agnostic 1 Sarcoma 1 Breast 1

Conditions

Sarcoma 2 Gliosarcoma 2 Glioblastoma 2 Stomach Neoplasms 1 Neuroblastoma 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Neoplasms 1 Neoplasm Metastasis 1 Hematologic Neoplasms 1 Glioma 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Brain Neoplasms 1

Interventions

pembrolizumab 11 Gemcitabine 10 Doxorubicin 10 Cyclophosphamide 9 Specimen Handling 8 Nivolumab 8 Ibandronic Acid 8 pazopanib 7 Radiosurgery 6 Magnetic Resonance Spectroscopy 6 Imatinib Mesylate 6 Biopsy 6 Bevacizumab 6 Irinotecan 5 regorafenib 4 Zoledronic Acid 4 Ipilimumab 4 Ifosfamide 4 Fluorouracil 4 Docetaxel 4 Cetuximab 4 sargramostim 3 conatumumab 3 cemiplimab 3 Sunitinib 3 Radiation 3 Paclitaxel 3 Leucovorin 3 Cryosurgery 3 Cisplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × capmatinib × Sarcoma × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡